RxDoctor Payments Data

Paul Selid, MD

Ophthalmology · Bismarck, NDNPI 1699186155

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,142 of the $1,357 with a category attached, or 84.1%. 12 manufacturers reported payments, led by Alcon at 45.0% of the total. Reporting peaked in 2022 at $616 and has fallen 70.9% since, to $180 in 2025.

$1,357in general payments, 2019–2025

Across 27 payments — averaging $50.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$610
  • Carl Zeiss Meditec USA, Inc.$215
  • NEW World Medical,inc.$210
  • Omeros Corporation$60
  • Amgen$59
  • AbbVie$47
  • plus $156 from 6 others

What the payments were for

  • Food & beverage$1,14284%
  • Other$21516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,357 in reported general payments places this provider in the 70th percentile of 41 ophthalmology providers in North Dakota.

See all ophthalmology providers in North Dakota

Medicare billing

Part B allowed, 2024
$1,685,579
Medicare patients
834
Services billed
23,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj16$504,497
RestasisCyclosporine73$51,979
Prednisolone Acetate706$41,718
Cyclosporine60$23,870
ValacyclovirValacyclovir Hcl242$11,218
Fluorometholone109$10,052
Latanoprost433$7,301
CombiganBrimonidine Tartrate/Timolol28$6,437
MoxifloxacinMoxifloxacin Hcl261$5,678
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$3,900
Ofloxacin262$3,900
Timolol Maleate103$1,796
Ketorolac Tromethamine44$869
ErythromycinErythromycin Base68$859
Doxycycline Monohydrate24$804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$47$58,416101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 41 ophthalmology providers in North Dakota.

Other ophthalmology in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →